Genome editing (GE) is one of the most efficient and useful molecular approaches to correct
the effects of gene mutations in hereditary monogenetic diseases, including β-thalassemia …

Abstract Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)‐Cas
technology possesses revolutionary potential to positively affect various domains of drug …

The clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated
endonuclease (Cas) system, referred to as CRISPR/Cas system, has attracted significant …

Traditional capillary isoelectric focusing (cIEF), liquid chromatography (LC) and capillary
zone electrophoresis (CZE) still suffered from low resolution for hemoglobinopathy …

In this short review, we presented and discussed studies on the expression of globin genes
in β-thalassemia, focusing on the impact of α-globin gene expression and α-globin modifiers …

The CRISPR/Cas9 technique is easily programmable, fast, more powerful, and efficient at
generating a mutation compared to previous gene therapy methods. β-thalassemia is the …

Thalassemias are monogenic hematologic diseases that are classified as α-or β-
thalassemia according to its quantitative abnormalities of adult α-or β-globin chains. β …

Simple Summary β-thalassemia syndromes are clinically and genetically heterogeneous
blood disorders presented by β-chain deficiency in hemoglobin production. Despite …

The potential to therapeutically alter the genome is one of the remarkable scientific
developments in recent years. Genome editing technologies have provided an opportunity …

Objective: Beta-thalassemia is a group of inherited hematologic. The most HBB gene variant
among Iranian beta-thalassemia patients is related to two mutations of IVSII-1 (G> A) and …